Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Mevalonate metabolism-dependent protein geranylgeranylation regulates thymocyte egress.

Du X, Zeng H, Liu S, Guy C, Dhungana Y, Neale G, Bergo MO, Chi H.

J Exp Med. 2019 Nov 13. pii: jem.20190969. doi: 10.1084/jem.20190969. [Epub ahead of print]

PMID:
31722972
2.

Association of Bariatric Surgery With Skin Cancer Incidence in Adults With Obesity: A Nonrandomized Controlled Trial.

Taube M, Peltonen M, Sjöholm K, Anveden Å, Andersson-Assarsson JC, Jacobson P, Svensson PA, Bergo MO, Carlsson LMS.

JAMA Dermatol. 2019 Oct 30:1-7. doi: 10.1001/jamadermatol.2019.3240. [Epub ahead of print]

PMID:
31664428
3.

The MTH1 inhibitor TH588 is a microtubule-modulating agent that eliminates cancer cells by activating the mitotic surveillance pathway.

Gul N, Karlsson J, Tängemo C, Linsefors S, Tuyizere S, Perkins R, Ala C, Zou Z, Larsson E, Bergö MO, Lindahl P.

Sci Rep. 2019 Oct 11;9(1):14667. doi: 10.1038/s41598-019-51205-w.

4.

Protein prenylation restrains innate immunity by inhibiting Rac1 effector interactions.

Akula MK, Ibrahim MX, Ivarsson EG, Khan OM, Kumar IT, Erlandsson M, Karlsson C, Xu X, Brisslert M, Brakebusch C, Wang D, Bokarewa M, Sayin VI, Bergo MO.

Nat Commun. 2019 Sep 4;10(1):3975. doi: 10.1038/s41467-019-11606-x.

5.

Inhibiting PGGT1B Disrupts Function of RHOA, Resulting in T-cell Expression of Integrin α4β7 and Development of Colitis in Mice.

López-Posadas R, Fastancz P, Martínez-Sánchez LDC, Panteleev-Ivlev J, Thonn V, Kisseleva T, Becker LS, Schulz-Kuhnt A, Zundler S, Wirtz S, Atreya R, Carlé B, Friedrich O, Schürmann S, Waldner MJ, Neufert C, Brakebusch CH, Bergö MO, Neurath MF, Atreya I.

Gastroenterology. 2019 Nov;157(5):1293-1309. doi: 10.1053/j.gastro.2019.07.007. Epub 2019 Jul 11.

6.

BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis.

Wiel C, Le Gal K, Ibrahim MX, Jahangir CA, Kashif M, Yao H, Ziegler DV, Xu X, Ghosh T, Mondal T, Kanduri C, Lindahl P, Sayin VI, Bergo MO.

Cell. 2019 Jul 11;178(2):330-345.e22. doi: 10.1016/j.cell.2019.06.005. Epub 2019 Jun 27.

PMID:
31257027
7.

Control of antiviral innate immune response by protein geranylgeranylation.

Yang S, Harding AT, Sweeney C, Miao D, Swan G, Zhou C, Jiang Z, Fitzgerald KA, Hammer G, Bergo MO, Kroh HK, Lacy DB, Sun C, Glogauer M, Que LG, Heaton NS, Wang D.

Sci Adv. 2019 May 29;5(5):eaav7999. doi: 10.1126/sciadv.aav7999. eCollection 2019 May.

8.

Targeting Filamin A Reduces Macrophage Activity and Atherosclerosis.

Bandaru S, Ala C, Salimi R, Akula MK, Ekstrand M, Devarakonda S, Karlsson J, Van den Eynden J, Bergström G, Larsson E, Levin M, Borén J, Bergo MO, Akyürek LM.

Circulation. 2019 Jul 2;140(1):67-79. doi: 10.1161/CIRCULATIONAHA.119.039697. Epub 2019 Apr 24.

PMID:
31014088
9.

Targeting the phospholipase A2 receptor ameliorates premature aging phenotypes.

Griveau A, Wiel C, Le Calvé B, Ziegler DV, Djebali S, Warnier M, Martin N, Marvel J, Vindrieux D, Bergo MO, Bernard D.

Aging Cell. 2018 Dec;17(6):e12835. doi: 10.1111/acel.12835. Epub 2018 Sep 14.

10.

Role of the C-terminal basic amino acids and the lipid anchor of the Gγ2 protein in membrane interactions and cell localization.

Noguera-Salvà MA, Guardiola-Serrano F, Martin ML, Marcilla-Etxenike A, Bergo MO, Busquets X, Escribá PV.

Biochim Biophys Acta Biomembr. 2017 Sep;1859(9 Pt B):1536-1547. doi: 10.1016/j.bbamem.2017.02.012. Epub 2017 Feb 21.

11.

Massive parallel sequencing questions the pathogenic role of missense variants in dilated cardiomyopathy.

Dalin MG, Engström PG, Ivarsson EG, Unneberg P, Light S, Schaufelberger M, Gilljam T, Andersson B, Bergo MO.

Int J Cardiol. 2017 Feb 1;228:742-748. doi: 10.1016/j.ijcard.2016.11.066. Epub 2016 Nov 9.

PMID:
27886618
12.

Targeting Zfp148 activates p53 and reduces tumor initiation in the gut.

Nilton A, Sayin VI, Zou ZV, Sayin SI, Bondjers C, Gul N, Agren P, Fogelstrand P, Nilsson O, Bergo MO, Lindahl P.

Oncotarget. 2016 Aug 30;7(35):56183-56192. doi: 10.18632/oncotarget.10899.

13.

What makes oncogenes mutually exclusive?

Cisowski J, Bergo MO.

Small GTPases. 2017 Jul 3;8(3):187-192. doi: 10.1080/21541248.2016.1212689. Epub 2016 Jul 14. Review.

14.

Control of the innate immune response by the mevalonate pathway.

Akula MK, Shi M, Jiang Z, Foster CE, Miao D, Li AS, Zhang X, Gavin RM, Forde SD, Germain G, Carpenter S, Rosadini CV, Gritsman K, Chae JJ, Hampton R, Silverman N, Gravallese EM, Kagan JC, Fitzgerald KA, Kastner DL, Golenbock DT, Bergo MO, Wang D.

Nat Immunol. 2016 Aug;17(8):922-9. doi: 10.1038/ni.3487. Epub 2016 Jun 6.

15.

Deficiency of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) Leads to Progressive Loss of Photoreceptor Function.

Christiansen JR, Pendse ND, Kolandaivelu S, Bergo MO, Young SG, Ramamurthy V.

J Neurosci. 2016 May 4;36(18):5107-14. doi: 10.1523/JNEUROSCI.0176-16.2016.

16.

Antioxidants can increase melanoma metastasis in mice.

Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyürek LM, Lindahl P, Nilsson J, Bergo MO.

Sci Transl Med. 2015 Oct 7;7(308):308re8. doi: 10.1126/scitranslmed.aad3740.

PMID:
26446958
17.

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.

Cisowski J, Sayin VI, Liu M, Karlsson C, Bergo MO.

Oncogene. 2016 Mar 10;35(10):1328-33. doi: 10.1038/onc.2015.186. Epub 2015 Jun 1.

PMID:
26028035
18.

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.

Staffas A, Karlsson C, Persson M, Palmqvist L, Bergo MO.

Leukemia. 2015 May;29(5):1032-40. doi: 10.1038/leu.2014.315. Epub 2014 Nov 5.

PMID:
25371176
19.

Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A.

Bandaru S, Zhou AX, Rouhi P, Zhang Y, Bergo MO, Cao Y, Akyürek LM.

Oncogenesis. 2014 Sep 22;3:e119. doi: 10.1038/oncsis.2014.33.

20.

Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53.

Sayin VI, Khan OM, Pehlivanoglu LE, Staffas A, Ibrahim MX, Asplund A, Agren P, Nilton A, Bergström G, Bergo MO, Borén J, Lindahl P.

Circ Res. 2014 Oct 10;115(9):781-9. doi: 10.1161/CIRCRESAHA.115.304992. Epub 2014 Sep 11.

PMID:
25212213
21.

Silencing RhoA inhibits migration and invasion through Wnt/β-catenin pathway and growth through cell cycle regulation in human tongue cancer.

Yan G, Zou R, Chen Z, Fan B, Wang Z, Wang Y, Yin X, Zhang D, Tong L, Yang F, Jiang W, Fu W, Zheng J, Bergo MO, Dalin M, Zheng J, Chen S, Zhou J.

Acta Biochim Biophys Sin (Shanghai). 2014 Aug;46(8):682-90. doi: 10.1093/abbs/gmu051.

PMID:
25001480
22.

Antioxidants accelerate lung cancer progression in mice.

Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO.

Sci Transl Med. 2014 Jan 29;6(221):221ra15. doi: 10.1126/scitranslmed.3007653.

23.

Myocardial KRAS(G12D) expression does not cause cardiomyopathy in mice.

Dalin MG, Zou Z, Scharin-Täng M, Safari R, Karlsson C, Bergo MO.

Cardiovasc Res. 2014 Feb 1;101(2):229-35. doi: 10.1093/cvr/cvt260. Epub 2013 Nov 20.

PMID:
24259500
24.

Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

Court H, Amoyel M, Hackman M, Lee KE, Xu R, Miller G, Bar-Sagi D, Bach EA, Bergö MO, Philips MR.

J Clin Invest. 2013 Nov;123(11):4681-94.

25.

Farnesyltransferase haplodeficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease.

Cheng S, Cao D, Hottman DA, Yuan L, Bergo MO, Li L.

J Biol Chem. 2013 Dec 13;288(50):35952-60. doi: 10.1074/jbc.M113.503904. Epub 2013 Oct 17.

26.

Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria.

Ibrahim MX, Sayin VI, Akula MK, Liu M, Fong LG, Young SG, Bergo MO.

Science. 2013 Jun 14;340(6138):1330-3. doi: 10.1126/science.1238880. Epub 2013 May 16.

27.

Zfp148 deficiency causes lung maturation defects and lethality in newborn mice that are rescued by deletion of p53 or antioxidant treatment.

Sayin VI, Nilton A, Ibrahim MX, Ågren P, Larsson E, Petit MM, Hultén LM, Ståhlman M, Johansson BR, Bergo MO, Lindahl P.

PLoS One. 2013;8(2):e55720. doi: 10.1371/journal.pone.0055720. Epub 2013 Feb 6.

28.

Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice.

Khan OM, Akula MK, Skålen K, Karlsson C, Ståhlman M, Young SG, Borén J, Bergo MO.

Circulation. 2013 Feb 19;127(7):782-90. doi: 10.1161/CIRCULATIONAHA.112.000588. Epub 2013 Jan 18.

29.

Targeting filamin A reduces K-RAS-induced lung adenocarcinomas and endothelial response to tumor growth in mice.

Nallapalli RK, Ibrahim MX, Zhou AX, Bandaru S, Sunkara SN, Redfors B, Pazooki D, Zhang Y, Borén J, Cao Y, Bergo MO, Akyürek LM.

Mol Cancer. 2012 Aug 2;11:50. doi: 10.1186/1476-4598-11-50.

30.

Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases.

Yang SH, Chang SY, Tu Y, Lawson GW, Bergo MO, Fong LG, Young SG.

J Lipid Res. 2012 Jan;53(1):77-86. doi: 10.1194/jlr.M021220. Epub 2011 Oct 28.

31.

RAS-converting enzyme 1-mediated endoproteolysis is required for trafficking of rod phosphodiesterase 6 to photoreceptor outer segments.

Christiansen JR, Kolandaivelu S, Bergo MO, Ramamurthy V.

Proc Natl Acad Sci U S A. 2011 May 24;108(21):8862-6. doi: 10.1073/pnas.1103627108. Epub 2011 May 9.

32.

Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice.

Khan OM, Ibrahim MX, Jonsson IM, Karlsson C, Liu M, Sjogren AK, Olofsson FJ, Brisslert M, Andersson S, Ohlsson C, Hultén LM, Bokarewa M, Bergo MO.

J Clin Invest. 2011 Feb;121(2):628-39. doi: 10.1172/JCI43758. Epub 2011 Jan 25.

33.

Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease.

Sjogren AK, Andersson KM, Khan O, Olofsson FJ, Karlsson C, Bergo MO.

Leukemia. 2011 Jan;25(1):186-9. doi: 10.1038/leu.2010.242. Epub 2010 Oct 26. No abstract available.

PMID:
20975663
34.

Filamin a mediates HGF/c-MET signaling in tumor cell migration.

Zhou AX, Toylu A, Nallapalli RK, Nilsson G, Atabey N, Heldin CH, Borén J, Bergo MO, Akyürek LM.

Int J Cancer. 2011 Feb 15;128(4):839-46. doi: 10.1002/ijc.25417.

35.

Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.

Liu M, Sjogren AK, Karlsson C, Ibrahim MX, Andersson KM, Olofsson FJ, Wahlstrom AM, Dalin M, Yu H, Chen Z, Yang SH, Young SG, Bergo MO.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6471-6. doi: 10.1073/pnas.0908396107. Epub 2010 Mar 22.

36.

Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.

Lee R, Chang SY, Trinh H, Tu Y, White AC, Davies BS, Bergo MO, Fong LG, Lowry WE, Young SG.

Hum Mol Genet. 2010 Apr 15;19(8):1603-17. doi: 10.1093/hmg/ddq036. Epub 2010 Jan 27.

37.

Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice.

Cutts BA, Sjogren AK, Andersson KM, Wahlstrom AM, Karlsson C, Swolin B, Bergo MO.

Blood. 2009 Oct 22;114(17):3629-32. doi: 10.1182/blood-2009-02-205146. Epub 2009 Aug 26.

PMID:
19710506
38.

Caution! Analyze transcripts from conditional knockout alleles.

Yang SH, Bergo MO, Farber E, Qiao X, Fong LG, Young SG.

Transgenic Res. 2009 Jun;18(3):483-9. doi: 10.1007/s11248-008-9237-9. Epub 2008 Dec 18.

39.

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.

Wahlstrom AM, Cutts BA, Liu M, Lindskog A, Karlsson C, Sjogren AK, Andersson KM, Young SG, Bergo MO.

Blood. 2008 Aug 15;112(4):1357-65. doi: 10.1182/blood-2007-06-094060. Epub 2008 May 23.

40.

Genetic analyses of the role of RCE1 in RAS membrane association and transformation.

Bergo MO, Wahlstrom AM, Fong LG, Young SG.

Methods Enzymol. 2008;438:367-89. doi: 10.1016/S0076-6879(07)38026-9. Review.

41.

GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.

Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C, Wahlstrom AM, Dalin M, Weinbaum C, Casey PJ, Tarkowski A, Swolin B, Young SG, Bergo MO.

J Clin Invest. 2007 May;117(5):1294-304.

42.

Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development.

Zhou X, Tian F, Sandzén J, Cao R, Flaberg E, Szekely L, Cao Y, Ohlsson C, Bergo MO, Borén J, Akyürek LM.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3919-24. Epub 2007 Feb 26.

43.

Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease.

Wahlstrom AM, Cutts BA, Karlsson C, Andersson KM, Liu M, Sjogren AK, Swolin B, Young SG, Bergo MO.

Blood. 2007 Jan 15;109(2):763-8. Epub 2006 Sep 14.

44.

Protein farnesyltransferase inhibitors and progeria.

Meta M, Yang SH, Bergo MO, Fong LG, Young SG.

Trends Mol Med. 2006 Oct;12(10):480-7. Epub 2006 Aug 30. Review.

PMID:
16942914
45.

A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.

Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, Majumdar S, Bergo MO, Young SG, Fong LG.

J Clin Invest. 2006 Aug;116(8):2115-21.

46.

Genetic and pharmacologic analyses of the role of Icmt in Ras membrane association and function.

Svensson AW, Casey PJ, Young SG, Bergo MO.

Methods Enzymol. 2006;407:144-59.

PMID:
16757321
47.

Prelamin A and lamin A appear to be dispensable in the nuclear lamina.

Fong LG, Ng JK, Lammerding J, Vickers TA, Meta M, Coté N, Gavino B, Qiao X, Chang SY, Young SR, Yang SH, Stewart CL, Lee RT, Bennett CF, Bergo MO, Young SG.

J Clin Invest. 2006 Mar;116(3):743-52.

48.

Endoproteolytic processing of RhoA by Rce1 is required for the cleavage of RhoA by Yersinia enterocolitica outer protein T.

Fueller F, Bergo MO, Young SG, Aktories K, Schmidt G.

Infect Immun. 2006 Mar;74(3):1712-7.

49.

Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.

Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, Meta M, Bendale P, Gelb MH, Young SG, Fong LG.

Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10291-6. Epub 2005 Jul 12.

50.

A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.

Winter-Vann AM, Baron RA, Wong W, dela Cruz J, York JD, Gooden DM, Bergo MO, Young SG, Toone EJ, Casey PJ.

Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4336-41.

Supplemental Content

Loading ...
Support Center